For the PSA range 3–20 ng/ml, the absolute risk difference for men with DRE+ status was 22–33% for GG ≥2 cancer (Fig. 2B) and 13–32% for GG ≥3 cancer (Fig. 2C). The gene discussed is KLK3; the disease is cancer.